This episode delivers a concise overview of the draft 12th amendment to the German Act Against Restrictions of Competition, published by the German Coalition Government on June 4. The discussion covers key changes, including higher turnover thresholds for routine acquisitions, expanded applicability of the Transaction Value Threshold (TVT), and the introduction of a new preliminary review phase. Learn how these updates could impact merger notifications, transaction reviews, and referrals to the European Commission.

Explore the latest Supreme Court decision in F.S. Credit Opportunities Corp. v. Sabec Capital Master Fund, LTD., as we break down the 6-3 ruling’s impact on the Investment Company Act of 1940. This episode explains why the Court found Section 47B does not grant private parties the right to sue for contract rescission, how activist investors had used this provision, and what the decision means for investment management companies and business development companies. Gain insights into strengthened anti-takeover defenses, reduced litigation risk, and the reaffirmed role of the SEC as primary enforcer.

Explore the latest updates to the U.S. Department of Defense 1260H list and their implications under the Biosecure Act on this episode. The hosts break down which Chinese companies were newly added, clarify distinctions between entities like Wuxi App Tech and Wuxi Biologics, and explain what these changes mean for federal contractors, grant recipients, and institutions. Learn about compliance timelines, upcoming prohibitions, key exemptions, and what steps organizations should take now to prepare.

This episode breaks down how the One Big Beautiful Bill Act (OBBA) expands the Section 4960 excise tax on executive compensation, shifting the definition of "covered employee" from the top five earners to any employee earning over $1 million. The discussion covers key changes, including preserved and eliminated exceptions for related organization employees, and clarifies the retroactive reach of the new rules.

This episode provides a concise update on New York’s health care transaction oversight following the 2026–2027 state budget. Hosts discuss the exclusion of proposed amendments, how New York’s requirements compare to other states, and what health care entities and investors should watch for next.

In this episode, we deliver a concise analysis of the SEC’s May 19, 2026 release proposing major amendments to the registered offering framework for business development companies (BDCs) and registered closed-end funds (CEFs). The discussion centers on the SEC’s push for parity between these funds and operating companies, including the elimination of public float thresholds, the introduction of new eligibility categories based on exchange listing and reporting compliance, and expanded access to short-form registration and shelf offerings. We also break down the implications for unlisted and non-traded funds, including federal preemption of state registration for certain BDCs and changes to Rule 473.

In this episode, we break down the SEC’s May 19, 2026 proposed amendments to the public company reporting framework. The discussion covers the most sweeping simplification of filer status in over twenty years, including the elimination of intermediate filer categories and a sharp increase in the large accelerated filer (LAF) threshold from $700 million to $2 billion. We explain how these changes will shift nearly 80% of public companies to non-accelerated filer (NAF) status, resulting in significant compliance cost reductions and streamlined reporting requirements.

In this episode, we provide a concise overview of Colorado’s newly enacted AI Act, SB 26189, which was signed into law on May 14, 2026, and replaces the previous 2024 legislation. The discussion covers the law’s delayed effective date of January 1, 2027, and highlights key changes, including the removal of the duty of care to avoid algorithmic discrimination and mandatory impact assessments. We break down the new documentation and record retention requirements for AI developers and deployers, consumer rights such as the ability to request correction instructions and human review, and the exclusive enforcement authority of the Colorado Attorney General.